Proteomics International Laboratories (ASX:PIQ) said its US reference laboratory in Irvine, California, received accreditation by the College of American Pathologists (CAP) based on the results of a recent on-site inspection, according to a Wednesday Australian bourse filing.
It completed the installation of a new mass spectrometry platform. It is employing this platform to establish its PromarkerEso diagnostic test to detect esophageal adenocarcinoma. It plans to launch the test in the US in 2026.
The firm's shares climbed 1% in recent trading on Wednesday.